ELF3 emerges as a novel prognostic indicator implicated in gastric cancer progression and correlated with unfavorable clinical outcomes

doi:10.4251/wjgo.v18.i5.116163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(29)

(28)

(0)

(34)

(573)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. May 15, 2026; 18(5): 116163
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.116163

Full Size Figure Download Figure

Figure 7 Correlation between E74-like ETS transcription factor 3 expression and immunomodulators in stomach adenocarcinoma. A: Heatmap of correlations between E74-like ETS transcription factor 3 (ELF3) and immune inhibitors across different cancers from TISIDB; B: Relationships between ELF3 and immune inhibitors in stomach adenocarcinoma, the results show a negative correlation; C: Heatmap of correlations between ELF3 and immune stimulants across different cancers from TISIDB; D: Relationships between ELF3 and immune stimulants in stomach adenocarcinoma, the results show a negative correlation. ELF3: E74-like ETS transcription factor 3; STAD: Stomach adenocarcinoma.

Citation: Sun ZS, Li CL, Jing HH, Wang ZZ, Zheng LB. ELF3 emerges as a novel prognostic indicator implicated in gastric cancer progression and correlated with unfavorable clinical outcomes. World J Gastrointest Oncol 2026; 18(5): 116163
URL: https://www.wjgnet.com/1948-5204/full/v18/i5/116163.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i5.116163

Sun ZS, Li CL, Jing HH, Wang ZZ, Zheng LB. ELF3 emerges as a novel prognostic indicator implicated in gastric cancer progression and correlated with unfavorable clinical outcomes. World J Gastrointest Oncol 2026; 18(5): 116163 [DOI: 10.4251/wjgo.v18.i5.116163]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.